Synergistic Suppression of Rat Neointimal Hyperplasia by Rapamycin and Imatinib Mesylate: Implications for the Prevention of Accelerated Arteriosclerosis

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Vascular Research

• Publication date

  2006-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000090948PMID 16410681
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Potent Inhibitory Effect of Sirolimus on Circulating Vascular Progenitor Cells

  2005cited by this paper
• SDF-1&agr;/CXCR4 Axis Is Instrumental in Neointimal Hyperplasia and Recruitment of Smooth Muscle Progenitor Cells

  2005cited by this paper
• Immediate and medium-term outcomes following the treatment of very long (> or =50 mm) chronic total coronary artery occlusions.

  2004cited by this paper
• Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement.

  2004influential reference
• Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: results of the restenosis cutting balloon evaluation trial (RESCUT).

  2004cited by this paper
• Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.

  2004cited by this paper
• Sirolimus‐Based Therapy Following Early Cyclosporine Withdrawal Provides Significantly Improved Renal Histology and Function at 3 Years

  2004cited by this paper
• Drug-eluting stents: new era and new concerns

  2004cited by this paper
• Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

  2003cited by this paper
• Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy

  2003cited by this paper
• Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy

  2003cited by this paper
• Pilot Trial of Oral Rapamycin for Recalcitrant Restenosis

  2003cited by this paper
• Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: results from the ISAR-STEREO trial.

  2003influential reference
• Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia

  2003cited by this paper
• Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial).

  2003cited by this paper
• Beneficial effect of rotational atherectomy with low platform speed on late outcomes.

  2003cited by this paper
• Rapamycin inhibits vascular remodeling in an experimental model of allograft vasculopathy and attenuates associated changes in fibrosis-associated gene expression.

  2003cited by this paper
• Platelet-derived growth factor receptor inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits

  2003cited by this paper
• Sirolimus (Rapamycin) Monotherapy Prevents Graft Vascular Disease in Nonhuman Primate Recipients of Orthotopic Aortic Allografts

  2003cited by this paper
• A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

  2002cited by this paper
• Oral Everolimus Inhibits In-Stent Neointimal Growth

  2002cited by this paper
• A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION

  2002cited by this paper
• Effect of p27 Deficiency and Rapamycin on Intimal Hyperplasia: In Vivo and In Vitro Studies Using a p27 Knockout Mouse Model

  2001cited by this paper
• FLUVASTATIN IN COMBINATION WITH RAD SIGNIFICANTLY REDUCES GRAFT VASCULAR DISEASE IN RAT CARDIAC ALLOGRAFTS1

  2001cited by this paper
• Prevention of neointimal proliferation by immunosuppression in synthetic vascular grafts.

  2001cited by this paper
• Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One-Year Angiographic and Intravascular Ultrasound Follow-Up

  2001cited by this paper
• Functional Blockade of Platelet-Derived Growth Factor Receptor-&bgr; but Not of Receptor-&agr; Prevents Vascular Smooth Muscle Cell Accumulation in Fibrous Cap Lesions in Apolipoprotein E–Deficient Mice

  2001cited by this paper
• Advances in therapeutic drug monitoring for immunosuppressants: a review of sirolimus. Introduction and overview.

  2000cited by this paper
• SIROLIMUS (RAPAMYCIN) HALTS AND REVERSES PROGRESSION OF ALLOGRAFT VASCULAR DISEASE IN NON-HUMAN PRIMATES1

  2000cited by this paper
• Therapeutic monitoring of sirolimus in human whole-blood samples by high-performance liquid chromatography.

  2000cited by this paper
• Incidence, progression and functional significance of cardiac allograft vasculopathy after heart transplantation.

  2000cited by this paper
• Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in non-human primates: trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickening

  2000cited by this paper
• Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats.

  1999cited by this paper
• Role of platelet-derived growth factor in obliterative bronchiolitis (chronic rejection) in the rat.

  1999cited by this paper
• Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle.

  1999cited by this paper
• Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model.

  1999cited by this paper
• Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin.

  1999cited by this paper
• Prevention of cardiac allograft arteriosclerosis by protein tyrosine kinase inhibitor selective for platelet-derived growth factor receptor.

  1999cited by this paper
• Expression and localization of platelet-derived growth factor ligand and receptor protein during acute and chronic rejection of rat cardiac allografts.

  1997cited by this paper
• Inhibition of platelet‐derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation

  1997cited by this paper
• Therapeutic blood levels of sirolimus (rapamycin) in the allografted rat.

  1996cited by this paper
• Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement.

  1995cited by this paper
• Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts.

  1995cited by this paper
• Side Effects of Rapamycin in the Rat

  1995cited by this paper
• Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels.

  1993cited by this paper
• Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF

  1991cited by this paper
• Influence of applied stress on mitotic response of arteries to injury with a balloon catheter: quantitative study in rat thoracic aorta.

  1989cited by this paper
• Synergy, additivism and antagonism in immunosuppression. A critical review.

  1977cited by this paper

• Pharmacological prevention of intimal hyperplasia: A state-of-the-art review.

  2022cites this paper
• Gleevec and Rapamycin Synergistically Reduce Cell Viability and Inhibit Proliferation and Angiogenic Function of Mouse Bone Marrow-Derived Endothelial Progenitor Cells

  2021cites this paper
• A Biodegradable Microneedle Cuff for Comparison of Drug Effects through Perivascular Delivery to Balloon-Injured Arteries

  2017cites this paper
• Effect of imatinib mesylate and rapamycin on the preformed intimal hyperplasia in rat carotid injury model

  2015cites this paper
• Different Responses of Neointimal Cells to Imatinib Mesylate and Rapamycin Compared with Normal Vascular Smooth Muscle Cells

  2014cites this paper
• Inhibition of intimal hyperplasia by local perivascular application of rapamycin and imatinib mesilate after carotid balloon injury

  2013cites this paper
• A biodegradable perivascular wrap for controlled, local and directed drug delivery.

  2012cites this paper
• Study on the effective screening of cell-selective peptides and the application for biomaterials

  2011cites this paper
• New molecular strategies for prevention of fibroproliferative vascular disease : An experimental approach to restenosis

  2009influential citation
• A new carotid artery transplantation model of rats

  2009cites this paper
• On the ability of imatinib mesylate to inhibit smooth muscle cell proliferation without delaying endothelialization: an in vitro study.

  2009cites this paper
• A new carotid artery transplantation model of rats

  2009cites this paper
• Vascular Cell Kinetics in Response to Intimal Injury ex vivo

  2009cites this paper
• Mechanisms behind the Synergistic Effect of Sirolimus and Imatinib in Preventing Restenosis after Intimal Injury

  2008cites this paper
• Medawar Prize Acceptance Speech

  2006cites this paper